Other substances

Merimepodib

IMPDH inhibitor

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro
Preprint 		VERO E6 cell cultures Apr/09/2020

AI-suggested references

Link Publication date
In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19.
Jul/22/2021
Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.
Jul/15/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04410354 Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 Terminated Phase 2 Jun/16/2020 Dec/01/2020
  • Alternative id - VC-02-01
  • Interventions - Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mayo Clinic in Arizona, Phoenix, Arizona, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Atlantic Health System / Overlook Medical Center, Summit, New Jersey, United States|St. David's South Austin Medical Center, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|HCA Houston Healthcare Medical Center, Houston, Texas, United States|HCA Houston Healthcare Mainland, Texas City, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 44
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of subjects not hospitalized or, if hospitalized, free of respiratory failure|Adverse Events|National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale|Temperature|Death|Mechanical ventilation|Vasopressor Support|Oxygen Therapy|Cessation of Viral Shedding|Change in Oxygen Saturation/Fraction of Inspired Oxygen
Export (.csv)